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pAbstract
Introduction: Five year survival for metastatic melanoma (MM) is very low at <10%.
Therapeutic options have been limited secondary to systemic toxicity. As a result
there has been a growing movement towards developing targeted drug delivery
models. Prior research of this group has demonstrated the effectiveness of acid-
prepared mesoporous spheres (APMS-TEG) in delivering chemotherapeutic agents at
a lower effective dose than systemic administration. This study aims to assess the
ability of the previously developed APMS-TEG particles to deliver therapeutic doses
of docetaxel for the treatment of melanoma.
Methods: In vitro experiments were performed to assess docetaxel loading onto
APMS-TEG particles and release kinetics. Toxicity experiments were performed using
docetaxel and docetaxel loaded APMS-TEG. The effect on cell growth was assessed
using the MelJuSo, UACC903, and WM1205 melanoma cell lines.
Results: Docetaxel demonstrated statistically significant dose dependent reduction in
growth of melanoma cells. In all three cell lines, doses of 1 nM were sufficient to
produce statistically significant reduction in cell growth. Scanning electron micrographs
demonstrate increased uptake of APMS-TEG particles by melanoma cells in the first
24 hours, with the majority within the first 4 hours. Unloaded APMS particles had no
effect on the melanoma cells, demonstrating that the particles themselves are not toxic.
APMS-TEG particles had a peak release of drug within the first hour, with equilibration
thereafter. The 5, 10, and 20 nM loaded particles all had statistically significant reduction
in cell growth than the control groups.
Discussion: The high potency against melanoma cells makes docetaxel a suitable
choice for loading into APMS-TEG particles. Docetaxel loaded APMS-TEG particles
demonstrate significant activity against malignant melanoma and thus offer an
innovative approach to the treatment of metastatic melanoma.
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The incidence of melanoma has been steadily increasing over the past few decades. In the
Caucasian population, the rate has tripled over the past 20 years [1]. Melanoma has be-
come the 6th most common cancer in the US, with an estimated 76,250 new cases in
2012 [2]. The true incidence however, may be even higher given underreporting of2015 Kaiser et al.; licensee Springer. This is an Open Access article distributed under the terms of the Creative Commons Attribution
icense (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium,
rovided the original work is properly credited.
Kaiser et al. Cancer Nanotechnology  (2015) 6:1 Page 2 of 8outpatient managed cases to cancer registries [3]. While melanoma accounts for only 4%
of all skin cancers, it is responsible for more than 74% of all skin cancer related deaths [1].
Five year survival for those with metastatic melanoma (MM), 2-5% of melanoma
diagnoses, is very low at <10% [4,5]. Therapeutic options for metastatic disease have
also been limited. The mainstays of adjuvant therapy consist of dacarbazine and high
dose interleukin-2 [5-7]. Chemotherapeutic drugs examined have included docetaxel
(DOC), paclitaxel, temozolomide (TMZ), vinorelbine, and others [4-6]. Despite the
number of chemotherapeutics that have activity against melanoma, these agents have
had limited clinical use due to their systemic toxicities. The past few years have seen
the arrival of ipilimumab and vemurafenib, which have improved survival in metastatic
melanoma [4,8]. However, even these agents have limitations in their applicability due
to their toxicity profiles.
As with other metastatic diseases, there has been a growing movement towards de-
veloping targeted drug delivery models in order to reduce systemic toxicity and
enhance tumor toxicity. Docetaxel, which binds and stabilizes microtubules leading to
mitotic arrest and eventually apoptosis, shows promise as an agent for targeted drug
delivery due to its potent activity against melanoma. To date, there has been work
from only two groups exploring the use of nanoparticles and nanomicelles to deliver
docetaxel for MM [9,10]. Zheng, et al. created a polymer based nanoparticle as a
delivery vehicle for DOC [9]. Though they show efficacy in killing melanoma cells,
the particles are limited as they can only be administered via intratumoral injection. Ma,
et al. describe preliminary work using nanomicelles loaded with chemotherapeutic agents,
including DOC [10].
Nanoparticles show promise for drug delivery due to their small size, but carry the
risk of systemic toxicity as well. By virtue of their size, these particles can enter and dis-
rupt functioning of cellular organelles [11]. In order to address the issue of systemic
toxicities, our prior research has focused on the development of a micro particle (1 –
3 μm diameter) that can be utilized for targeted drug delivery due to its porous nature
[11]. These acid-prepared mesoporous spheres tagged with tetra ethylene glycol
(APMS-TEG or APMS) have been proven to deliver chemotherapeutic agents to tumor
cells at a lower effective dose than systemic administration [12]. Additionally, these par-
ticles have been demonstrated to show minimal systemic toxicity [11,12]. This study
aims to assess the ability of the previously developed APMS-TEG particles to deliver
therapeutic doses of DOC for the treatment of melanoma.Methods
Human melanoma cell lines and reagents
Three human malignant melanoma cell lines, MelJuSo, UACC903, and WM1205, were
obtained from the University of Vermont. All cells were maintained in 50:50 Dulbecco’s
Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F12) containing 5% fetal bovine
serum (FBS) and supplemented with penicillin (50 units/mL), streptomycin (100 μg/mL),
hydrocortisone (100 μg/mL), insulin (2.5 μg/mL), transferrin (2.5 μg/mL), and selenium
(2.5 μg/mL), and incubated at 37°C in 5% CO2. Cells were passaged weekly at a 1:10 ratio
in to new flasks. Docetaxel (DOC) was obtained from Sigma (St Louis, MO.)
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Cells were plated into 12 well plates at a density of 25,000 cells per well in 0.5 mL of
medium described above and allowed to adhere for 2 – 3 hours before treatment. Varying
doses of DOC (with equal total amounts of dimethyl sulfoxide (DMSO), the solvent
control) were made up in fresh media and 0.5 mL was added to cells already plated to
achieve the desired final concentrations of DOC. At 24, 48 and 72 h, cells were trypsi-
nized, collected, and counted with a heamocytometer to determine average total cell
numbers remaining at each time point for each dose.Scanning Electron Microscopy (SEM) of APMS-TEG interacting with MelJuSo melanoma
cells
Acid prepared mesoporous spheres (APMS) tagged with tetra ethylene glycol (TEG)
(APMS-TEG complex) were synthesized by Dr. Christopher Landry at the University
of Vermont as previously described [11]. MelJuSo cells were grown to confluence on
thermonox plastic coverslips (Nalge Nunc International, Naperville, IL) and were ad-
ministered APMS-TEG particles (0.1 mg/mL). At 1, 4 and 24 hours, coverslips were
fixed and prepared for SEM analysis as done previously [11]. In summary, coverslips
were washed 2× for 5 minutes with 0.1 M Millonig’s phosphate buffer (pH 7.2), then
fixed in 1:1 H2O dilution of Karnovsky’s fixative (2.5% glutaraldehyde, 1% parafor-
maldehyde) at 4°C for 45 minutes. Samples were then washed with Millonig’s phos-
phate buffer (pH 7.2), and post-fixed in osmium tetroxide (OsO4) at 4°C for 30–45
minutes. Samples were then dehydrated in graded ethanols, from 35% to 100%. Sam-
ples were critical point dried using liquid CO2 as the transition fluid in a Samdri
PVT-3B critical point dryer (Tousimis Research Corporation, Rockville, MD). Speci-
mens were mounted on aluminum specimen stubs using conductive graphite paint
and allowed to dry, and were sputter-coated for 4–5 min with gold and palladium in
a Polaron sputter coater (Model 5100; Quorum Technologies, Guelph, ON, Canada).
Cells and APMS-TEG particles were then imaged on a JSM 6060 scanning electron
microscope (JEOL USA, Inc., Peabody, MA) [11].Melanoma cell growth in response to docetaxel loaded APMS micro particles
APMS particles (2 mg) were incubated with increasing concentrations of docetaxel in
5 mL sterile distilled water for 24 – 72 h at 4°C on a rocking platform. APMS particles
were then spun down to remove unloaded docetaxel still in solution, washed in water,
spun down again and resuspended in 5 mL of fresh media. A 0.5 mL suspension of the
loaded particles in media of each docetaxel concentration were then added to respect-
ive wells of a 12 well plate containing previously plated cells as described above. Con-
trols used were DMSO alone, APMS (0.2 mg/mL) and 1 nM unloaded docetaxel.
Concentrations of docetaxel indicated in these experiments represent the concentration
of docetaxel in the loading solution and thus the maximal concentration of DOC that
can be released if there is complete uptake and release from the APMS-TEG particles.
Cells were collected at 24, 48, and 72 hours and total cell numbers were counted as de-
scribed above.
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APMS particles (2 mg) were incubated with increasing concentrations of docetaxel in
5 mL sterile distilled water for 48 hours at 4°C on a rocking platform. APMS-TEG parti-
cles were then spun down with supernatant collected to quantitate the amount of
unloaded docetaxel still in solution (unloaded). The particles were washed in water, spun
down again, with the supernatant collected to quantitate the amount of DOC lost with
washing (wash). Particles were resuspended in 10 mL of fresh media. A 1 mL suspension
of the loaded particles in media of each docetaxel concentration was then added to re-
spective wells of a 12 well plate. The control used was APMS (0.2 mg/mL) with no doce-
taxel. Concentrations of docetaxel indicated in these experiments represent the
concentration of docetaxel in the loading solution and thus the maximal concentration of
DOC released if there is complete uptake and release from the APMS-TEG particles.
Media samples were collected at 1, 2, 4, 8, 24, and 48 hours.High performance liquid chromatography for detection of docetaxel
As per the protocol developed by Andersen, et al., a 3 μm Purospher STAR RP-18e
(3×125 mm) column from EMD Millipore (Darmstadt, Germany) was obtained and
maintained at 55°C [13]. Mobile phase consisted of 20 mM dibasic potassium phos-
phate buffer (pH 3): acetonitrile (57.5:42.5 v/v) run at 0.8 mL/min. Docetaxel peaks
were seen between 7 – 8 minutes using a UV detector set to 227 nm. Fresh buffer and
standards were prepared daily.Statistics
Statistical analysis was performed using GraphPad Prism 5.03/6.00. All data was analyzed
by one way ANOVA followed by the Newman-Keuls Multiple Comparison Test or a stu-
dent’s t test where indicated. Data with p <0.05 were determined to be significant.Results
Docetaxel was chosen as the model agent based on prior studies demonstrating melanoma
cell death at doses in the nanomolar range [9]. DOC demonstrated statistically significant
dose dependent reduction in growth of melanoma cells (Figure 1). In all three cell
lines, doses of 1 nM were sufficient to reduce melanoma cell growth, which was
statistically significant. A stronger and more uniform effect was observed at doses
between 5 and 20 nM.
APMS-TEG particles were successfully prepared using the previously described tech-
nique. [11] Particles were administered to melanoma cells and examined under a scanning
electron microscope (SEM) at varying time points (Figure 2). The SEM images demonstrate
increased uptake of APMS-TEG particles by the melanoma cells over a 24 hour time
course. Much of the particles are taken in within the first 4 hours, with little remaining in
the extracellular space by 24 hours.
Varying concentrations of DOC were loaded into the APMS-TEG particles as described
above and compared to directly administering a 1 nM dose of DOC and to particles with
no DOC loaded. The first thing noted is that the unloaded particle has no effect on the
Figure 1 Dose response of docetaxel (DOC) on the growth of 3 melanoma cell lines (a – c).
*, significant (p < 0.05) from 0 nM at 72 h.
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ticles loaded with higher concentrations of DOC achieved higher reductions of cell growth
in all cell lines, similar to the results seen with unloaded DOC (Figure 1). The only
exception to this is for the 1 nM loaded particles. These particles had a smaller effect
than directly giving 1 nM of DOC (Figure 3, right panel). Though the loaded 1 nM
particles had a smaller effect than the unloaded dose, the reduction in cell growth
was still statistically significant in both the MelJuSo and UACC903 cell lines. The 5,
10, and 20 nM loaded particles all had statistically significant higher reduction in cell
growth than any of the control groups.
Analysis of the APMS-TEG particle loading and release kinetics demonstrates that
essentially all the DOC is loaded into the particles after mixing (Figure 4, unloaded).
Additionally, a minimal amount is lost in the wash step. In the 1 nM loaded particle,
the peak concentration is 2 nM and diminishes after the first hour. For the remaining
particles, all had statistically significant higher levels of DOC released into solution. All
the particles have a peak release of drug within the first hour, with equilibration
thereafter.
Figure 2 Scanning electron micrograph showing MelJuSo melanoma cell uptake of APMS-TEG at different
time points at two magnifications. a) at one hour, b) at 4 hours and c) at 24 hours. Scale bar = 10 μm
top row, 1 μm bottom row.
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Our study demonstrated that DOC loaded APMS-TEG particles significantly reduce
the growth of melanoma. The high potency against melanoma cells makes DOC a suit-
able choice for loading into APMS-TEG particles. In addition, scanning electron mi-
croscopy demonstrates that these particles are readily taken up by melanoma cells in a
relatively short time frame.Figure 3 Growth curves of melanoma cell lines. (a – c) Left: Growth curves of three melanoma cell lines
using APMS-TEG loaded with different concentrations of DOC. Right: Cell counts at 72 hours. *, significant
(p < 0.05) from 0 nM (unloaded, negative control). †, significant (p < 0.05) from 0 nM (loaded in APMS-TEG,
negative particle control). ‡, significant (p < 0.05) from 1 nM (unloaded, positive DOC control).
Figure 4 DOC loaded APMS-TEG release kinetics. *, significant (p < 0.05) from 0 nM at the same time
point. t, significant (p < 0.05) by t test. All other significance was determined by one way ANOVA and a
Newman-Keuls test for pairwise comparisons.
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dependent reduction in cell growth. The particles do not demonstrate saturation with
drug at doses as high as 20 nM. We see peak release of drug within 1 hour and this is
sustained thereafter. The fact that we do not see all of the drug released in the 20 nM
loaded particle is potentially a result of particles reaching equilibrium with the media it
is suspended in. However, further studies are required to fully elucidate the release kin-
etics of DOC from the particles.
The toxicity profile of the APMS-TEG particles and mesoporous silica in general, is
favorable when examining reviews of the existing literature. Nanoparticle formulations
of mesoporous silica have been shown to be non-toxic with no evidence of inflamma-
tion in rat tendon, kidney, heart, and liver over 30 days after injection [14]. It can be
safely administered subcutaneously, intravenously, and via intra-peritoneal routes with
good bioavailability [15]. Mesoporous silica does not have carcinogenic potential [16].
These APMS-TEG particles have previously been shown to be non-immunogenic and
non-toxic [11].
At this juncture, future directions for this model are twofold. The first goal is to move
into animal models to validate in-vivo activity against melanoma cells. The second will be
to characterize the pharmacokinetics and pharmacodynamics of the particle. This will
include attaching functional moieties to the particle that will allow for targeted delivery of
the particles to melanoma cells.Conclusions
APMS-TEG particles have previously demonstrated effectiveness at delivering chemo-
therapeutic drugs for other cancers, notably mesothelioma [11]. These early studies
demonstrate that APMS-TEG particles can be used to deliver chemotherapeutic agents
which could be used for the treatment of melanoma. Because these particles have been
shown to be non-toxic and do not elicit an immune response, the problem of systemic
toxicity associated with nanoparticle based delivery systems is reduced. Docetaxel
loaded APMS-TEG particles demonstrate significant activity against malignant melan-
oma and thus offer a novel approach to the treatment of the disease.
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